We’re looking forward to receiving the next round of applications for trials that will be supported by the recently launched Alzheimer’s Clinical Trial Consortium (ACTC).
They say that time flies when you’re having fun. The field of geroscience has grown tremendously since our summits in 2013 and 2016, and now we find ourselves moving faster than ever and planning a third summit. This time, our goal will be to engage professional societies, stakeholder groups, and researchers interested in specific chronic diseases and conditions of older people, and exchange ideas on the role of aging biology in these health problems.
If we roll back the clock 12 months, we’ll see that, back then, NIA issued a call for administrative supplements for existing NIA grantees to add an aim on Alzheimer’s disease (and its related dementias) to a grant that was not already studying Alzheimer’s or its related dementias. This year, we decided to open the field up a little and include other NIH institutes.
We’re looking forward to attending the annual meeting of the American Geriatrics Society, May 3–5, in Orlando, Florida. NIA and the AGS Research Committee are offering two symposia—one for junior researchers new to aging and one for senior researchers. We hope to see you in Orlando.
At NIA, we share an ambitious goal with our colleagues in the research community: To understand the nature of aging and the aging process and diseases and conditions associated with growing older in order to extend healthy, active years of life for all Americans. But the basic biologists, clinicians, behavioral research specialists, demographers, and experts in dozens of other scientific specialties supported by NIA will necessarily have different interests, concerns, and strategies toward achieving that common goal.
The signing of the Consolidated Appropriations Act of 2018 a couple of weeks ago provided a $414 million increase in our budget for Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). On top of that, it provided a $111 million increase in our general budget. With that much gas in our tank, as soon as the ink on the Act was dry, NIA sprang into action.
On March 25–27, the NIA welcomed current and former grantees from more than 26 medical and surgical specialties, along with mentors who are leaders in aging research within their specialties, to the third biennial meeting of GEMSSTAR (Grants for Early Medical/Surgical Specialists' Transition to Aging Research) Scholars. The meeting featured a combination of aging-themed presentations, Scholars’ posters, career development training, and networking opportunities.
Now is the time! NIA's small business programs offer up to $1.5 million in no-strings-attached funding
If you run a small business, are thinking of starting a small business, or have an idea focused on Alzheimer's disease and Alzheimer’s-related dementias (AD/ADRD) that has a commercial side, then this blog is for you! Whether your focus is therapeutic drug development, systems of care, effects on families, or something else, there are opportunities for you through our small business research and development programs – known as SBIR (Small Business Innovation Research) and STTR (Small Business Technology Transfer Research).
March Madness—a time for bracket busting and bragging rights, Cinderella stories and unexpected outcomes. And, so it goes in NIA-supported research, too! We in the Division of Behavioral and Social Research have been developing our game in new directions—funding more research in Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD).
The public’s investment in health research is considerable, supporting the NIH to find answers to some of the nation’s most vexing health problems. At NIA, we know that an aging population is paying particular attention to research, hoping for treatments—and advice—to stave off a myriad of conditions that too often accompany advancing years. One of the best ways to share accurate information with the public is to tell them about your research.
Seeking your ideas for ways to enhance recruitment and retention of Alzheimer’s disease study participants
It’s hard to recruit people for clinical research these days. And that is doubly true if the topic is Alzheimer’s disease and its related dementias. Recruiting volunteer participants is a primary, persistent bottleneck that poses unique challenges to clinical trials researchers.